Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Technosphere Insulin 10U+ 20U · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TI 30 units (10 unit + 20 unit | EXPERIMENTAL | Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge |
| TI 30 units (30 unit cartridge | EXPERIMENTAL | Technosphere® Insulin 30 units given as one 30 unit cartridge |
| Name | Type | Description |
|---|---|---|
| Technosphere® Insulin 10U + 20U | DRUG | Inhaled Insulin |
| Technosphere® Insulin 30U | DRUG | Inhaled Insulin |
Inclusion Criteria: * Men and women aged 18 to 45 years, considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis * No smoking in the past 6 months (including cigarettes, cigars, and pipes) * Urine cotinine testing \< 100 ng/mL * Body mass inde...
Technosphere Insulin 10U+ 20U is an investigational small molecule being developed by MannKind Corporation (MNKD) for use in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being studied to compare the same dosage of insulin using a combination of cartridges, specifically 30 units as 2 cartridges versus 1 cartridge.
Technosphere Insulin 10U+ 20U is an insulin product, so it targets insulin receptors in the body to regulate glucose metabolism. As an insulin formulation, it is designed to deliver insulin to help control blood sugar levels. The drug is being studied in healthy volunteers to assess its pharmacokinetics and pharmacodynamics.
Technosphere Insulin 10U+ 20U is developed by MannKind Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol MNKD. The company is conducting clinical trials to evaluate this insulin formulation in healthy volunteers.
Technosphere Insulin 10U+ 20U is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial involving healthy volunteers to evaluate its safety and pharmacokinetics.
Technosphere Insulin 10U+ 20U has one completed clinical trial registered under NCT01902121. This Phase 1 study, titled 'Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge,' enrolled 40 healthy volunteers in the United States. The trial was controlled but not double-blinded.
Technosphere Insulin 10U+ 20U is a specific formulation of insulin developed by MannKind Corporation. It is designed to deliver insulin via a unique technosphere technology. While it contains insulin, it is distinct from other insulin products due to its delivery mechanism and cartridge configuration being studied in clinical trials.